Identification of ROBO1 as a Novel Hepatocellular Carcinoma Antigen and a Potential Therapeutic and Diagnostic Target
Open Access
- 1 June 2006
- journal article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 12 (11) , 3257-3264
- https://doi.org/10.1158/1078-0432.ccr-05-2787
Abstract
Purpose: Hepatocellular carcinoma is the most common primary malignancy of the liver and accounts for as many as one million deaths annually worldwide. The present study was done to identify new transmembrane molecules for antibody therapy in hepatocellular carcinoma. Experimental Design: Gene expression profiles of pooled total RNA from three tissues each of moderately differentiated and poorly differentiated hepatocellular carcinoma were compared with those of normal liver, noncancerous liver tissue in hepatocellular carcinoma patients, 30 normal tissue samples, and five fetal tissue samples. Target genes up-regulated specifically in hepatocellular carcinoma were validated by immunohistochemical analysis and complement-dependent cytotoxicity assay using monoclonal antibodies generated against target molecules. Results: The human homologue of the Drosophila Roundabout gene, axon guidance receptor homologue 1, ROBO1/DUTT1, a member of the immunoglobulin superfamily, was highly expressed in hepatocellular carcinoma, whereas it showed only a limited distribution in normal tissues. On immunohistochemical analysis using a newly generated anti-ROBO1 monoclonal antibody, positive signals were observed in 83 of 98 cases of hepatocellular carcinoma (84.7%). The mAb B2318C induced complement-dependent cytotoxicity in ROBO1-expressing cell lines and in the liver cancer cell line PLC/PRF/5. Strikingly, the ectodomain of ROBO1 was detected not only in the culture medium of liver cancer cell lines (PLC/PRF/5, HepG2, etc.) but also in sera from hepatocellular carcinoma patients (6 of 11). Conclusions: This is the first report that ROBO1 is overexpressed in hepatocellular carcinoma and shed into serum in humans. These observations suggest that ROBO1 is a potential new serologic marker for hepatocellular carcinoma and may represent a new therapeutic target.Keywords
This publication has 18 references indexed in Scilit:
- Expression of the LXRα Protein in Human Atherosclerotic LesionsArteriosclerosis, Thrombosis, and Vascular Biology, 2005
- Identification and validation of cell surface antigens for antibody targeting in oncologyEndocrine-Related Cancer, 2004
- Targeted Disruption of the 3p12 Gene, Dutt1/Robo1, Predisposes Mice to Lung Adenocarcinomas and Lymphomas with Methylation of the Gene PromoterCancer Research, 2004
- Identification of Soluble NH2-Terminal Fragment of Glypican-3 as a Serological Marker for Early-Stage Hepatocellular CarcinomaCancer Research, 2004
- Expression profiling in multistage hepatocarcinogenesis: Identification of HSP70 as a molecular marker of early hepatocellular carcinomaHepatology, 2003
- Glypican‐3, overexpressed in hepatocellular carcinoma, modulates FGF2 and BMP‐7 signalingInternational Journal of Cancer, 2002
- Identification of Genes Associated with Dedifferentiation of Hepatocellular Carcinoma with Expression Profiling AnalysisJapanese Journal of Cancer Research, 2002
- Tumour specific promoter region methylation of the human homologue of the Drosophila Roundabout gene DUTT1 (ROBO1) in human cancersOncogene, 2002
- The Generation of Monoclonal Antibodies against Human Peroxisome Proliferator-activated Receptors (PPARs)Journal of Atherosclerosis and Thrombosis, 2002
- Insight into hepatocellular carcinogenesis at transcriptome level by comparing gene expression profiles of hepatocellular carcinoma with those of corresponding noncancerous liverProceedings of the National Academy of Sciences, 2001